High-Risk Myelodysplastic Syndrome
Showing 1 - 25 of >10,000
High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston
Completed
- High Risk Myelodysplastic Syndrome
- +2 more
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Nov 21, 2022
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- (no location specified)
Sep 18, 2023
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
- HDM201
- +2 more
-
Durham, North Carolina
- +8 more
Dec 13, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk
Recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +5 more
- Gemtuzumab Ozogamicin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial
Recruiting
- Recurrent Chronic Myelomonocytic Leukemia
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)
Recruiting
- Myelodysplastic Syndromes
- 50 gm CIVI/24 hours x 5 days every 4 week
-
Miami, Florida
- +1 more
Jul 6, 2022
Acute Myeloid Leukemia, MDS Trial (SPRX002, ARC-T)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- SPRX002
- ARC-T
- (no location specified)
Jul 12, 2022
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte, New York, Houston (BTX-A51)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
-
Duarte, California
- +2 more
Sep 8, 2022
Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)
Recruiting
- Leukemia
- Cladribine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 23, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Sacramento (Lenalidomide)
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
-
Sacramento, CaliforniaUniversity of California Davis
Mar 8, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial
Completed
- Relapsed Acute Myeloid Leukemia (AML)
- +2 more
-
Atlanta, Georgia
- +5 more
Apr 4, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)
Not yet recruiting
- Myelodysplastic Syndrome
- +4 more
- UAE Inhibitor TAK-243
- (no location specified)
Oct 20, 2022
Leukemia Trial in Houston (Vosaroxin, Decitabine)
Completed
- Leukemia
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 13, 2022
Leukemia, Acute, AML, Adult, ALL, Adult Trial in Charlottesville (Palliative Care Visits)
Recruiting
- Leukemia, Acute
- +3 more
- Palliative Care Visits
-
Charlottesville, VirginiaUniversity of Virginia
Apr 28, 2022
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid
Active, not recruiting
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- +9 more
-
Sewell, New Jersey
- +4 more
Dec 13, 2022
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Azacitidine
- +2 more
-
Baltimore, Maryland
- +2 more
Feb 25, 2022
Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)
Not yet recruiting
- Acute Myeloid Leukemia
- High-Risk and Very High-Risk Myelodysplastic Syndromes
- (no location specified)
Jul 25, 2023